<p>根据 MarketBeat 的报道，覆盖 Theravance Biopharma, Inc.（NASDAQ:TBPH - 获取免费报告）的八位分析师给出了 “适度买入” 的共识推荐。三位分析师对该股票给予了持有评级，三位给予了买入评级，另外两位则给予了强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价格为 21.3333 美元。</p>
<p>获取 <strong>Theravance Biopharma</strong> 的提醒：</p>
<p>最近，一些分析师对 TBPH 股票发布了报告。BTIG Research 在 3 月 20 日的报告中重申了 “买入” 评级，并对 Theravance Biopharma 的股票设定了 21.00 美元的目标价。HC Wainwright 在 3 月 2 日的报告中将 Theravance Biopharma 的目标价从 20.00 美元上调至 27.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在周日的研究报告中将 Theravance Biopharma 的股票评级从 “持有” 上调至 “强烈买入”。Oppenheimer 在 3 月 5 日的研究报告中将 Theravance Biopharma 的股票评级从 “跑赢大盘” 下调至 “市场表现”。最后，B. Riley Financial 在 3 月 4 日的研究报告中重新发布了 “中性” 评级，并将 Theravance Biopharma 的目标价设定为 14.00 美元（从 28.00 美元下调）。</p>
<p><strong>查看我们最新的 TBPH 股票分析</strong></p>
<h2>Theravance Biopharma 股票表现</h2>
<p>NASDAQ TBPH 在周二开盘价为 15.26 美元。Theravance Biopharma 的 52 周低点为 7.90 美元，52 周高点为 21.03 美元。该股票的 50 日移动平均价格为 17.40 美元，200 日移动平均价格为 16.94 美元。该股票的市值为 7.8574 亿美元，市盈率为 7.52，贝塔值为 0.17。</p>
<h2>内部活动</h2>
<p>在相关消息中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。该股票以平均价格 13.96 美元出售，总交易额为 433,695.32 美元。出售后，该高级副总裁持有 232,699 股公司股票，价值约为 3,248,478.04 美元。这代表了他们持有股票的比例下降了 11.78%。该交易已在 SEC 的法律文件中披露，可以通过此超链接访问。公司内部人士持有公司股票的 6.90%。</p>
<h2>机构资金流入和流出</h2>
<p>机构投资者最近对该股票的持仓进行了调整。Vanguard Group Inc.在第三季度将其在 Theravance Biopharma 的股份增加了 2.5%。Vanguard Group Inc.目前拥有 2,211,582 股该生物制药公司的股票，价值 32,289,000 美元，此前在上个季度购买了 54,152 股。State Street Corp 在第四季度将其在 Theravance Biopharma 的股份增加了 4.4%。State Street Corp 目前拥有 1,101,892 股该生物制药公司的股票，价值 20,616,000 美元，此前在上个季度购买了 45,987 股。Geode Capital Management LLC 在第四季度将其在 Theravance Biopharma 的持股增加了 4.5%。Geode Capital Management LLC 目前拥有 938,724 股该生物制药公司的股票，价值 17,567,000 美元，此前在上个季度购买了 40,734 股。Dimensional Fund Advisors LP 在第四季度将其在 Theravance Biopharma 的持股增加了 12.0%。Dimensional Fund Advisors LP 目前拥有 858,957 股该生物制药公司的股票，价值 16,072,000 美元，此前在上个季度购买了 92,253 股。最后，Arrowstreet Capital Limited Partnership 在第三季度购买了 Theravance Biopharma 的新股份，价值 10,611,000 美元。机构投资者和对冲基金持有公司 99.10% 的股票。</p>
<h2>Theravance Biopharma 公司简介</h2>
<p>（获取免费报告）</p>
<p>Theravance Biopharma 是一家生物制药公司，专注于创新药物的发现、开发和商业化，主要涉及呼吸系统疾病、炎症和免疫学以及罕见疾病领域。该公司开发的小分子疗法旨在通过靶向特定的分子通路来满足未满足的医疗需求。其主要市场产品 YUPELRI®（revefenacin）吸入溶液是美国批准的首个也是唯一一个每日一次的长效抗胆碱药物（LAMA）。</p>
<h2>推荐故事</h2>
<ul>
<li>我们更看好的五只股票超过 Theravance Biopharma</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
<h2>你现在应该投资 1,000 美元在 Theravance Biopharma 吗？</h2>
<p>在你考虑 Theravance Biopharma 之前，你会想听听这个。</p>
<p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Theravance Biopharma 并不在名单上。</p>
<p>虽然 Theravance Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

Theravance生物制药

<p>Theravance Biopharma, Inc.（纳斯达克代码：TBPH）获得了八位分析师的 “适度买入” 共识推荐。平均目标价为 21.33 美元，其中三位分析师给予持有评级，三位给予买入评级，二位给予强烈买入评级。最近的报告显示，BTIG Research 维持买入评级，目标价为 21.00 美元，而 HC Wainwright 将其目标价从 20.00 美元上调至 27.00 美元。该股票开盘价为 15.26 美元，52 周区间为 7.90 美元至 21.03 美元。机构投资者持有该公司 99.10% 的股份</p>

<p>Shares of Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) have been given a consensus recommendation of &#34;Moderate Buy&#34; by the eight analysts that are covering the company, MarketBeat reports. Three analysts have rated the stock with a hold rating, three have assigned a buy rating and two have issued a strong buy rating on the company. The average 12 month target price among analysts that have issued a report on the stock in the last year is $21.3333.</p>
<div class="lb-trans"><p>根据 MarketBeat 的报道，覆盖 Theravance Biopharma, Inc.（NASDAQ:TBPH - 获取免费报告）的八位分析师给出了 “适度买入” 的共识推荐。三位分析师对该股票给予了持有评级，三位给予了买入评级，另外两位则给予了强烈买入评级。在过去一年中，发布报告的分析师对该股票的平均 12 个月目标价格为 21.3333 美元。</p>
</div><p>Get <strong>Theravance Biopharma</strong> alerts:</p>
<div class="lb-trans"><p>获取 <strong>Theravance Biopharma</strong> 的提醒：</p>
</div><p>A number of analysts have recently issued reports on TBPH shares. BTIG Research reiterated a &#34;buy&#34; rating and issued a $21.00 price objective on shares of Theravance Biopharma in a report on Friday, March 20th. HC Wainwright increased their target price on shares of Theravance Biopharma from $20.00 to $27.00 and gave the stock a &#34;buy&#34; rating in a report on Monday, March 2nd. Wall Street Zen raised shares of Theravance Biopharma from a &#34;hold&#34; rating to a &#34;strong-buy&#34; rating in a research report on Sunday. Oppenheimer lowered shares of Theravance Biopharma from an &#34;outperform&#34; rating to a &#34;market perform&#34; rating in a research note on Thursday, March 5th. Finally, B. Riley Financial reissued a &#34;neutral&#34; rating and set a $14.00 price target (down from $28.00) on shares of Theravance Biopharma in a research report on Wednesday, March 4th.</p>
<div class="lb-trans"><p>最近，一些分析师对 TBPH 股票发布了报告。BTIG Research 在 3 月 20 日的报告中重申了 “买入” 评级，并对 Theravance Biopharma 的股票设定了 21.00 美元的目标价。HC Wainwright 在 3 月 2 日的报告中将 Theravance Biopharma 的目标价从 20.00 美元上调至 27.00 美元，并给予该股票 “买入” 评级。Wall Street Zen 在周日的研究报告中将 Theravance Biopharma 的股票评级从 “持有” 上调至 “强烈买入”。Oppenheimer 在 3 月 5 日的研究报告中将 Theravance Biopharma 的股票评级从 “跑赢大盘” 下调至 “市场表现”。最后，B. Riley Financial 在 3 月 4 日的研究报告中重新发布了 “中性” 评级，并将 Theravance Biopharma 的目标价设定为 14.00 美元（从 28.00 美元下调）。</p>
</div><p><strong>Check Out Our Latest Stock Analysis on TBPH</strong></p>
<div class="lb-trans"><p><strong>查看我们最新的 TBPH 股票分析</strong></p>
</div><h2>Theravance Biopharma Stock Performance</h2>
<div class="lb-trans"><h2>Theravance Biopharma 股票表现</h2>
</div><p>NASDAQ TBPH opened at $15.26 on Tuesday. Theravance Biopharma has a 52 week low of $7.90 and a 52 week high of $21.03. The stock's 50 day moving average price is $17.40 and its two-hundred day moving average price is $16.94. The stock has a market capitalization of $785.74 million, a price-to-earnings ratio of 7.52 and a beta of 0.17.</p>
<div class="lb-trans"><p>NASDAQ TBPH 在周二开盘价为 15.26 美元。Theravance Biopharma 的 52 周低点为 7.90 美元，52 周高点为 21.03 美元。该股票的 50 日移动平均价格为 17.40 美元，200 日移动平均价格为 16.94 美元。该股票的市值为 7.8574 亿美元，市盈率为 7.52，贝塔值为 0.17。</p>
</div><h2>Insider Activity</h2>
<div class="lb-trans"><h2>内部活动</h2>
</div><p>In related news, SVP Rhonda Farnum sold 31,067 shares of the company's stock in a transaction dated Monday, March 16th. The stock was sold at an average price of $13.96, for a total transaction of $433,695.32. Following the sale, the senior vice president owned 232,699 shares in the company, valued at approximately $3,248,478.04. This represents a 11.78% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is accessible through this hyperlink. Corporate insiders own 6.90% of the company's stock.</p>
<div class="lb-trans"><p>在相关消息中，SVP Rhonda Farnum 在 3 月 16 日的交易中出售了 31,067 股公司的股票。该股票以平均价格 13.96 美元出售，总交易额为 433,695.32 美元。出售后，该高级副总裁持有 232,699 股公司股票，价值约为 3,248,478.04 美元。这代表了他们持有股票的比例下降了 11.78%。该交易已在 SEC 的法律文件中披露，可以通过此超链接访问。公司内部人士持有公司股票的 6.90%。</p>
</div><h2>Institutional Inflows and Outflows</h2>
<div class="lb-trans"><h2>机构资金流入和流出</h2>
</div><p>Institutional investors have recently made changes to their positions in the stock. Vanguard Group Inc. raised its stake in shares of Theravance Biopharma by 2.5% during the 3rd quarter. Vanguard Group Inc. now owns 2,211,582 shares of the biopharmaceutical company's stock worth $32,289,000 after purchasing an additional 54,152 shares in the last quarter. State Street Corp grew its stake in shares of Theravance Biopharma by 4.4% in the fourth quarter. State Street Corp now owns 1,101,892 shares of the biopharmaceutical company's stock valued at $20,616,000 after buying an additional 45,987 shares in the last quarter. Geode Capital Management LLC increased its holdings in Theravance Biopharma by 4.5% during the fourth quarter. Geode Capital Management LLC now owns 938,724 shares of the biopharmaceutical company's stock worth $17,567,000 after buying an additional 40,734 shares during the last quarter. Dimensional Fund Advisors LP increased its holdings in Theravance Biopharma by 12.0% during the fourth quarter. Dimensional Fund Advisors LP now owns 858,957 shares of the biopharmaceutical company's stock worth $16,072,000 after buying an additional 92,253 shares during the last quarter. Finally, Arrowstreet Capital Limited Partnership bought a new stake in Theravance Biopharma during the third quarter worth $10,611,000. Institutional investors and hedge funds own 99.10% of the company's stock.</p>
<div class="lb-trans"><p>机构投资者最近对该股票的持仓进行了调整。Vanguard Group Inc.在第三季度将其在 Theravance Biopharma 的股份增加了 2.5%。Vanguard Group Inc.目前拥有 2,211,582 股该生物制药公司的股票，价值 32,289,000 美元，此前在上个季度购买了 54,152 股。State Street Corp 在第四季度将其在 Theravance Biopharma 的股份增加了 4.4%。State Street Corp 目前拥有 1,101,892 股该生物制药公司的股票，价值 20,616,000 美元，此前在上个季度购买了 45,987 股。Geode Capital Management LLC 在第四季度将其在 Theravance Biopharma 的持股增加了 4.5%。Geode Capital Management LLC 目前拥有 938,724 股该生物制药公司的股票，价值 17,567,000 美元，此前在上个季度购买了 40,734 股。Dimensional Fund Advisors LP 在第四季度将其在 Theravance Biopharma 的持股增加了 12.0%。Dimensional Fund Advisors LP 目前拥有 858,957 股该生物制药公司的股票，价值 16,072,000 美元，此前在上个季度购买了 92,253 股。最后，Arrowstreet Capital Limited Partnership 在第三季度购买了 Theravance Biopharma 的新股份，价值 10,611,000 美元。机构投资者和对冲基金持有公司 99.10% 的股票。</p>
</div><h2>Theravance Biopharma Company Profile</h2>
<div class="lb-trans"><h2>Theravance Biopharma 公司简介</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Theravance Biopharma is a biopharmaceutical company focused on the discovery, development and commercialization of innovative medicines, primarily in the areas of respiratory disease, inflammatory and immunology, and rare disorders. The company develops small-molecule therapies designed to address unmet medical needs by targeting specific molecular pathways. Its lead marketed product, YUPELRI® (revefenacin) inhalation solution, is the first and only once-daily, long-acting muscarinic antagonist (LAMA) approved by the U.S.</p>
<div class="lb-trans"><p>Theravance Biopharma 是一家生物制药公司，专注于创新药物的发现、开发和商业化，主要涉及呼吸系统疾病、炎症和免疫学以及罕见疾病领域。该公司开发的小分子疗法旨在通过靶向特定的分子通路来满足未满足的医疗需求。其主要市场产品 YUPELRI®（revefenacin）吸入溶液是美国批准的首个也是唯一一个每日一次的长效抗胆碱药物（LAMA）。</p>
</div><h2>Recommended Stories</h2>
<div class="lb-trans"><h2>推荐故事</h2>
</div><ul>
<li>Five stocks we like better than Theravance Biopharma</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票超过 Theravance Biopharma</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/RatingsChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9VEJQSA" alt="" original-src="https://www.marketbeat.com/scripts/RatingsChart.ashx?Prefix=NASDAQ&amp;Symbol=TBPH"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，以便为读者提供最快的报道和公正的覆盖。请将任何问题或意见发送至 contact@marketbeat.com。</em></p>
</div><h2>Should You Invest $1,000 in Theravance Biopharma Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Theravance Biopharma 吗？</h2>
</div><p>Before you consider Theravance Biopharma, you'll want to hear this.</p>
<div class="lb-trans"><p>在你考虑 Theravance Biopharma 之前，你会想听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Theravance Biopharma wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 跟踪华尔街顶级评级和表现最佳的研究分析师及其每天推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前立即购买……而 Theravance Biopharma 并不在名单上。</p>
</div><p>While Theravance Biopharma currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Theravance Biopharma 目前在分析师中获得了适度买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

Theravance 生物制药公司（NASDAQ:TBPH）被分析师给予平均评级为 “适度买入”